malondialdehyde has been researched along with barbituric acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antolovich, M; Jardine, D; Prenzler, PD; Robards, K | 1 |
| Chen, L; Chen, Z; Cheng, L; Deng, C; Jiang, W; Li, S; Ma, L; Xiang, M; Xie, C; Zheng, H | 1 |
2 other study(ies) available for malondialdehyde and barbituric acid
| Article | Year |
|---|---|
Liquid chromatography-mass spectrometry (LC-MS) investigation of the thiobarbituric acid reactive substances (TBARS) reaction.
Topics: Barbiturates; Chromatography, Liquid; Linoleic Acid; Lipid Peroxidation; Malondialdehyde; Mass Spectrometry; Thiobarbiturates; Thiobarbituric Acid Reactive Substances | 2002 |
A novel agonist of PPAR-γ based on barbituric acid alleviates the development of non-alcoholic fatty liver disease by regulating adipocytokine expression and preventing insulin resistance.
Topics: 3T3-L1 Cells; Adipocytes; Adipokines; AMP-Activated Protein Kinases; Animals; Barbiturates; Carnitine O-Palmitoyltransferase; Cell Differentiation; Down-Regulation; Fatty Liver; Gene Expression Regulation; Gene Expression Regulation, Enzymologic; Glucose; Hep G2 Cells; Humans; Insulin Resistance; Liver; Male; Malondialdehyde; Mice; Non-alcoholic Fatty Liver Disease; PPAR gamma; Rats; Rats, Wistar; Triglycerides; Up-Regulation | 2011 |